The dCas9‐AID was stably expressed in K562 cells, a chronic myelogenous leukaemia (CML) line that contains the BCR‐ABL oncogene and is sensitive to imatinib. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.